Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696420 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8205008 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8373505 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8373486 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8315263 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8549614 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8374769 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL3113016 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8192951 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL7364818 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4054715-A1 | BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901362-A | Bivalent LECA inhibitors against pseudomonas aeruginosa biofilm formation | 赫姆霍尔兹传染病研究中心有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112898734-B | Liquid crystal polymer interlocking network and preparation method and application thereof | 中山大学 | 2022-03-15 | — | — | CN | disclosed |
| US-20130018140-A1 | N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKING AGENTS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES | DICKMEIS MARCUS (DE) | 2013-01-17 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| EP-0696585-B1 | NOVEL BISOXADIAZOLIDINE DERIVATIVE | YAMANOUCHI PHARMA CO LTD (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5643931-A | ANTIDIABETIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0696585-A1 | NOVEL BISOXADIAZOLIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
| US-5063240-A | Hypoglycemic, antilipemic | BEECHAM GROUP P.L.C. (GB) | 1991-11-05 | — | — | US | disclosed |
| EP-0397453-A1 | Novel bis-2,4-dioxothiazolidines | Beecham Group p.l.c. (GB) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | NQO2, SQOR, CPS1 | ALDH1A1 2545/4885SMN1; SMN2 3993/4885MAPT 4732/4885 |
| US-20130018140-A1 | N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKING AGENTS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES | PNN, PARN, NCLN | ALDH1A1 1538/4885SMN1; SMN2 1718/4885MAPT 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.